Investment - Fast Facts
Independent survey shows value of investment meetings
At AusBiotech 2011, research and consulting firm, Insync Surveys, conducted an independent and confidential review of the AusBiotech Life Science Investment Summit, which has been held annually since 2009. 50% of 42 companies responded and 31% of 97 investors who attended all three events (2009, 2010 and 2011) responded.
The objectives of the survey were to:
Help participating companies and supporters to quantify the value of investor meetings
Track the outcomes of specific investment events in commercial terms for investors
Quantify the level of investment biotechnology brings to the economy for governments
Investors were asked to estimate the value of deals they expect from investment discussions they initiated at the 2011 Investment Summit, and the actual value of deals that were done as a result of the 2010 and 2009 events. The result shows that at the very least, $33 million has been generated for presenting companies. Data for the value expected to be generated from deals in discussion as a result of the 2011 event, suggests the Summit will generate even greater value than previous years.
The results of the survey revealed that significant value was generated and that the value has steadily increased since 2009, demonstrating the positive contribution the investment events are making to the Australian biotech industry.
The Most Powerful Investment Sector of the Twenty-First Century
Now is the time to invest in Australian biotechnology. AusBiotech believes that biotech has the potential to create unprecedented wealth for its investors, and that the market will soon be flooded with biotechnology products. Biotech pipelines are deep, and there is a large aging population with the need for new and effective drugs. And while the industry is experiencing an increasing swell in talent as well as impressive revenue growth, the Food and Drug Administration’s (FDA) drug approvals keep validating its momentum.
In it's 50 years, biotechnology has produced many historical milestones
1953 introduction of the double helix
1966 the genetic code was cracked
1976 the first biotechnology company formed, Genentech
1982 the first biotech drug approved by FDA; human Insulin
1994 the fist breast cancer gene is discovered
2001 the complete sequence of human genome was published
2004 the FDA approved the first anti-angiogenic drug for cancer; Avastin
Cancer patients, in particular, are benefiting from recent biotechnology developments. A decade ago there were less than a dozen oncology drugs in clinical trials, most of which were highly toxic chemotherapies. Today there are over 400 targeted biotech medicines, including cancer drugs (with minimal side effects), being tested. With new drugs and treatments popping up everyday, the future surely holds many more cures for patients as well as opportunities for investors.
A Unique Time for Investors
Over the last ten years, developments in biotechnology have been significant and the future holds the potential for many cures and advancements in the medical world.
Biotechnology's impressive discoveries have made it a premier industry, it has
Produced deep product pipelines
Demonstrated impressive revenue growth
Created life-saving drugs and treatments
Drawn qualified talent to the industry
Improved the regulatory environment
Gained strategic alignments with big pharma companies and governments organizations
The trend of increased healthcare spending and technology advancements, the unmet medical needs for cures and treatments will continue to provide the biotech sector with growth and advancements, as well as lucrative investment opportunities.